Safety Monitoring in Clinical Trials
Open Access
- 17 January 2013
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 5 (1), 94-106
- https://doi.org/10.3390/pharmaceutics5010094
Abstract
Monitoring patient safety during clinical trials is a critical component throughout the drug development life-cycle. Pharmaceutical sponsors must work proactively and collaboratively with all stakeholders to ensure a systematic approach to safety monitoring. The regulatory landscape has evolved with increased requirements for risk management plans, risk evaluation and minimization strategies. As the industry transitions from passive to active safety surveillance activities, there will be greater demand for more comprehensive and innovative approaches that apply quantitative methods to accumulating data from all sources, ranging from the discovery and preclinical through clinical and post-approval stages. Statistical methods, especially those based on the Bayesian framework, are important tools to help provide objectivity and rigor to the safety monitoring process.Keywords
This publication has 8 references indexed in Scilit:
- Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information: Part 4: One methodContemporary Clinical Trials, 2011
- Planning and core analyses for periodic aggregate safety data reviewsClinical Trials, 2011
- Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting teamClinical Trials, 2009
- Payment of clinical research subjectsJCI Insight, 2005
- Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithmStatistics in Medicine, 2001
- Practical Bayesian Guidelines for Phase IIB Clinical TrialsBiometrics, 1994
- Sequential Tests of Statistical HypothesesThe Annals of Mathematical Statistics, 1945